Alpha 2.0
Login Register
» Authors » D Grinblatt

D Grinblatt

Explore the profile of D Grinblatt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 50
Followers 0
Related Specialties
General Surgery
Biochemistry
Oncology
Top 10 Co-Authors
S F Williams
J Mehta
S Singhal
L Kaminer
O Frankfurt
A O Evens
L I Gordon
A M Evens
R Meagher
J N Winter
Published In
Bone Marrow Transplant
Biochem Biophys Res Commun
Cytotherapy
Invest New Drugs
Affiliations
Soon will be listed here.
Recent Articles
1.
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Mehta J, Gordon L, Tallman M, Winter J, Evens A, Evens A, et al.
Bone Marrow Transplant . 2006 Jun; 38(2):95-100. PMID: 16751789
Sixty three patients aged 27-66 years (median 52) were allografted from HLA-matched sibling (n=47), 10 of 10 allele-matched unrelated (n=19), or one-antigen/allele-mismatched (n=7) donors aged 24-69 years (median 46) after...
2.
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation
Singhal S, Gordon L, Tallman M, Winter J, Evens A, Evens A, et al.
Bone Marrow Transplant . 2006 Jan; 37(6):553-7. PMID: 16444282
Whether the CD34+ and CD3+ cell doses in allogeneic HSCT should be estimated using actual (ABW) or ideal (IBW) body weight has never been definitively determined. We have shown that...
3.
Autologous and allogeneic transplantation for aggressive NHL
Smith S, Grinblatt D, Van Besien K
Cytotherapy . 2002 Aug; 4(3):223-40. PMID: 12194719
Background: Intermediate- and high-grade NHL are generally chemosensitive diseases with high initial response rates to combination chemotherapy. Dose intensification via autologous and allogeneic transplantation provides viable treatment options in specific...
4.
Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer
Lazarus H, Winton E, Williams S, Grinblatt D, Campion M, Cooper B, et al.
Bone Marrow Transplant . 1995 Jun; 15(6):935-42. PMID: 7581094
Our purpose was to determine the maximum tolerated dosage of rhIL-6 after high-dose cytotoxic chemotherapy and autologous BMT in patients with advanced breast cancer. Twenty patients (median age 43.5 years)...
5.
Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck
Kies M, Grinblatt D, Runge-Morris M, Blough R, Watkins A, Taylor 4th S
Invest New Drugs . 1994 Jan; 12(1):45-7. PMID: 7960605
The Illinois Cancer Center entered 25 patients on a phase II trial of intravenous melphalan treating patients with recurrent, metastatic or locally advanced and inoperable squamous cell carcinoma of the...
6.
Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP
Hoppel C, Grinblatt D, Kwok H, Arora P, Singh M, Sayre L, et al.
Biochem Biophys Res Commun . 1987 Oct; 148(2):684-93. PMID: 3500717
In order to clarify the structural requirements associated with the inhibition of mitochondrial respiration by MPP+, the neurotoxic metabolites of the Parkinsonian agent MPTP, ten sets of pyridine/N-methylpyridinium pairs and...